Amgen Inc/ US0311621009 /
15/11/2024 22:00:00 | Chg. -12.3200 | Volume | Bid01:51:13 | Ask01:51:13 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
283.6100USD | -4.16% | 5.33 mill. Turnover: 962.21 mill. |
283.0000Bid Size: 300 | 283.6300Ask Size: 100 | 152.45 bill.USD | 3.05% | 22.58 |
GlobeNewswire
29/08
Great Place To Work Announces the 2024 Best Workplaces in Asia Representing 6.9 Million Employee Exp...
GlobeNewswire
28/08
Prevent Cancer Annual Gala to celebrate three decades of commitment to cancer prevention and early d...
GlobeNewswire
15/08
Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of ...
GlobeNewswire
12/08
TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
08/08
CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
08/08
Ardelyx Appoints Experienced Biopharma Executive, Eric Foster, as Chief Commercial Officer
GlobeNewswire
05/08
Avalyn Appoints Erin Lavelle, Seasoned Biopharma Finance Executive, to its Board of Directors
GlobeNewswire
01/08
CytomX Therapeutics to Report Second Quarter 2024 Financial Results on August 8, 2024
GlobeNewswire
22/07
Oxford BioTherapeutics Named Best Tech SME of the Year at Thames Valley Tech & Innovation Awards 202...
GlobeNewswire
02/07
Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Bi...